Hopp til hovedinnhold

Psoriasis

Sist oppdatert: Sist revidert:
Sist revidert av:

Definisjon:
Er en kronisk, residiverende, inflammatorisk hudsykdom med multifaktorielle årsaker. 20% har psoriasis artritt
Forekomst:
Prevalens av psoriasis varierer fra 0,5% til 4,6%
Symptomer:
Utslett og kløe, ev. polyartritt hos 10-40%
Funn:
Velavgrensede, erytematøse skjellende elementer på ekstensorsidene av kroppen og på hodet. Ev. artrittforandringer
Diagnostikk:
Ingen tilleggsundersøkelser er vanligvis påkrevd, bortsett ev. fra hudbiopsi
Behandling:
Lokalbehandling er tilstrekkelig for de fleste, men 20% trenger systemisk behandling der særlig biologiske legemiddel er et stort fremskritt
  1. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015 Sep 5;386(9997):983-94. PMID: 26025581. PubMed  
  2. Weigle N, McBane S. Psoriasis. Am Fam Physician 2013; 87: 626-33. PubMed  
  3. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386(10012):2489-98. PubMed  
  4. Patrisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-85. PubMed  
  5. Armstrong AW, Mehta MD, Schupp CW,et al. Psoriasis Prevalence in Adults in the United States. JAMA Dermatol. 2021 Jun 30. PMID: 34190957.
  6. Gelfand JM, Stern RS, Nijsten T, et al. The prevalence of psoriasis in African Americans: results from a population-based. J Am Acad Dermatol. 2005;52:23-26. PubMed  
  7. Hoff M, Malm Gulati A, Romundstad PR, et al. Prevalence and incidence rates of psoriatic arthritis in central Norway: data from the Nord-Trøndelag Health Study (HUNT). Ann Rheum Dis 2015; 74: 60–64.
  8. Alinaghi F, Calov M, Kristensen LE, et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019 Jan;80(1):251-265.e19. PMID: 29928910. PubMed  
  9. Horn EJ, Fox KM, Patel V, et al. Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. J Am Acad Dermatol. 2007;57(6):957-62. PubMed  
  10. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263-71. PubMed  
  11. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509. PubMed  
  12. Langenbruch A, Radtke MA, Krensel M, Jacobi A, Reich K, Augustin M. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014 Nov. 171(5):1123-8.
  13. Meffert J. Psoriasis. Medscape, last updated Apr 06, 2017. emedicine.medscape.com  
  14. Chen T-L, Lee L-L, Huang H-K, et al. Association of Psoriasis With Incident Venous Thromboembolism and Peripheral Vascular Disease A Systematic Review and Meta-analysis. JAMA Dermatol 2021. pmid:34851364 PubMed  
  15. Chiricozzi A. Psoriasis. BMJ Best Practice, last updated 30 Oct 2020.
  16. Philipp S, Wolk K, Kreutzer S, et al. The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder. Expert Opin Ther Targets 2006;10:817-831. PubMed  
  17. Ryan C, Menter A. Psoriasis and cardiovascular disorders. G Ital Dermatol Venereol 2012; 147: 189-202. pmid:22481581 PubMed  
  18. European Dermatology Forum. Living EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris. Last updated 07/2020. www.edf.one  
  19. Smith CH, Jabbar-Lopez ZK, Yiu ZZ, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177(3):628-36. PubMed  
  20. Millsop JW, Bhatia BK, Debbaneh M, Koo J, Liao W. Diet and psoriasis, part III: role of nutritional supplements. J Am Acad Dermatol. 2014 Sep;71(3):561-9. PMID: 24780177. PubMed  
  21. Schlager JG, Rosumeck S, Werner RN, Jacobs A, Schmitt J, Schlager C, Nast A. Topical treatments for scalp psoriasis. Cochrane Database of Systematic Reviews 2016, Issue 2. Art. No.: CD009687. DOI: 10.1002/14651858.CD009687.pub2. DOI  
  22. Samarasekera EJ, Sawyer L, Wonderling D, et al. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. British Journal of Dermatology 2013; 168: 954-67. doi:10.1111/bjd.12276 DOI  
  23. Wang C, Lin A. Efficacy of topical calcineurin inhibitors in psoriasis. J Cutan Med Surg. 2014;18(1):8-14. PubMed  
  24. Lapolla W, Yentzer BA, Bagel J, et al. A review of phototherapy protocols for psoriasis treatment. J Am Acad Dermatol. 2011;64:936-949. PubMed  
  25. Jabbar-Lopez ZK, Wu KC, Reynolds NJ. Newer agents for psoriasis in adults. BMJ. 2014;349:g4026. doi: 10.1136/bmj.g4026. DOI  
  26. Montaudie H, Sbidian E, Paul C, et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Europ Acad Dermatol Venereol. 2011;25(suppl 2):12-18.
  27. Maza A, Montaudie H, Sbidian E, et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Euro Acad Dermatol Venereol. 2011;25(suppl 2):19-27. PMID: 21388455. PubMed  
  28. Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. Cochrane Database of Systematic Reviews 2020, Issue 1. Art. No.: CD011535. The Cochrane Library  
  29. Meng Y, Dongmei L, Yanbin P, et al. Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis. Clin Exp Dermatol. 2014;39(6):696-707. doi: 10.1111/ced.12390.
  30. Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etarnecept for moderate- to severe psoriasis. N Engl J Med 2010; 362: 118-28. New England Journal of Medicine  
  31. Langley RG, Elewski BE, Lebwohl MN, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371:326-338. PubMed  
  32. Hammadi AA. Psoriatic arthritis. Medscape, last updated Dec 11, 2014.
  33. Leisner MZ, Riis JL, Schwartz BS et al. Psoriasis and Risk of Mental Disorders in Denmark. JAMA Dermatol 2019.0039 pmid:31066861 PubMed  
  34. Mason AR, Mason J, Cork M, et al. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev 2013; :CD005028. Cochrane (DOI)  
  35. Dupire G, Droitcourt C, Hughes C, Le Cleach L. Antistreptococcal interventions for guttate and chronic plaque psoriasis. Cochrane Database of Systematic Reviews 2019, Issue 3. Art. No.: CD011571. DOI: 10.1002/14651858.CD011571.pub2. DOI  
  36. Pouplard C, Brenaut E, Horreau C, et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013;27(suppl 3):36-46. PMID: 23845151 PubMed  
  37. Trafford AM, Parisi R, Kontopantelis E, et al. Association of Psoriasis With the Risk of Developing or Dying of Cancer A Systematic Review and Meta-analysis. JAMA Dermatol 2019. pmid:31617868 PubMed  
  38. Ahlehoff O, Gislason GH, Charlot M et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011; 270: 147-57. PubMed  
  39. Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med 2012. doi:10.1111/j.1365-2796.2012.02593.x DOI  
  40. Li X, Andersen KM, Chang H-Y, et al. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis 2019. pmid:31672774 PubMed  
  41. Crowley JJ, Weinberg JM, Wu JJ et al. Treatment of Nail Psoriasis. JAMA Dermatol 2015; 151(1): 87-94. pmid:25471223 PubMed  
  42. Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 2009; 61: 1373-8. pmid:19790120 PubMed  
  • Terje Johannessen, professor i allmennmedisin, Trondheim

Tidligere fagmedarbeidere

  • Theis Huldt-Nystroem, spesialist i hudsykdommer
  • Morten Dalaker, avtalespesialist i hudsykdommer, Trondheim Hudlegesenter, Carl Johans gt 3, 7010 Trondheim
  • Sylvi Torvund, spesialist i allmennmedisin, Nidarvold legesenter, Trondheim